Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. - Wikidata - wikimedia - TriplyDB

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37404368

about

Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis Diabetes mellitus and metformin in hepatocellular carcinoma Biomarkers of cancer angioprevention for clinical studies Update on the treatment of type 2 diabetes mellitus Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.The Repurposing Drugs in Oncology (ReDO) Project.Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress.Diabetic oncopathy--one more yet another deadly diabetic complication!Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity.Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas.Metformin therapy and prostate cancer risk: a meta-analysis of observational studies.Metformin: a modulator of bevacizumab activity in cancer? A case report Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients.Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis.Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative.Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics.Metformin therapy associated with survival benefit in lung cancer patients with diabetes Metformin: are potential benefits on cancer risk extended to cancer survival?Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Prognostic value of glycated hemoglobin in colorectal cancer.Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats.Future treatments of cirrhosis.Obesity and breast cancer: not only a risk factor of the disease.Expanding the therapeutic spectrum of metformin: from diabetes to cancer.Drug repurposing in oncology--patient and health systems opportunities.Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival.A phase Ib study of everolimus combined with metformin for patients with advanced cancer.The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.Metformin: A Hopeful Promise in Aging Research.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.

P2860

Q26738743-D8B97EC2-B31B-471A-9E02-67BB1F9C75A0 Q26741205-8E9A27F5-F8CE-49AE-B246-228EE1BE34AD Q26774580-48F84039-05CD-4776-93F4-81B7ECC28278 Q28073342-BFE7E7A0-A54C-4240-883D-BD908B06D30C Q28074225-84A9A80D-FEE3-47B4-8286-D0660745C6D2 Q33648824-6A2E9AD8-1C43-449B-89F4-4A5A635532A8 Q33893949-F0AFB343-34BC-42A6-B7BF-3F0B0357B695 Q33915937-899FB90D-FC90-45D7-A8F9-619D36F93AFF Q34272097-A5F1F529-A8A5-471E-9832-4676481A9047 Q35084900-ACBBF130-4008-4ABA-B56B-1248276EFD06 Q35144264-4712FB38-4DED-440D-B63A-B91FEA968652 Q35149589-A773EEF9-0E17-44C0-BDBA-7F085AF243D0 Q35558619-21BBA0F0-10B2-4382-9520-818B0C644CE6 Q35586709-A4BB4311-4DE7-4305-8A41-1B6FF9043DB9 Q35769609-C3899DA3-8041-4F8C-85A4-BCA7CD813002 Q35981176-A58695BC-5EEC-49B8-87D1-6F2D7025F5CA Q36182935-47C987F8-9A5F-4A55-8079-64C61A07AD0D Q36214971-E4062DD2-9154-4207-89E0-88E7BCA97139 Q36410079-5560A08D-0028-4CAC-B7A3-D5E1C7E52595 Q36428086-FC30C503-30DA-47D4-9D2F-BBAF085D4519 Q36478779-7901ADEC-EF4A-4308-81AC-22B136C1B159 Q36794283-9A9C26D7-152F-40CB-8466-0F61B1DE9ED6 Q37118676-D6553CEA-4EF2-4627-BEEC-51EAEB8AEBDB Q37246561-2F3DF5E7-7DDC-4A46-8236-11D5839966C2 Q37376577-E76C97DF-26BD-4A8C-B8B9-681FB603C9FA Q37404363-87D7D326-5B69-4F74-8379-A66D799741C8 Q37458763-6972913C-5D2C-46C9-B21F-F6F070195037 Q37483467-46261BED-D6D6-4EA7-B69B-DD08950B65AA Q37720435-BE4DFC13-7ACA-4288-9A5A-A3482E847AF9 Q38218607-1BCD9C83-27CC-45ED-AC6E-5900794C9CBC Q38436984-6AB3BC9A-0E33-4198-8B63-43B28F813276 Q38558943-D916F2B6-FED3-47A3-ABB5-505567C7FD66 Q38611707-499C5FC2-4434-427A-BA9B-688AA41DCD4A Q38663388-B19B59D1-8BEB-4796-9CB5-25CE9D9B11C1 Q38670844-B73002FA-69D2-4A0D-9FF3-BABFCE5C5085 Q38728567-1B22FED9-3214-4971-8256-F71F93AD7532 Q38738859-9414C21A-DE36-49FF-8A6E-4BA2D2E584F1 Q38756907-D499FF07-1135-4F10-945B-3DC92FC86AE5 Q38792334-30BE5E92-8211-42FB-8EFC-AE52C5347310 Q38835936-BB43C37C-49C6-4795-BAAB-B73F186A816F

P2860

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37404368

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Metformin is associated with s ...... atic review and meta-analysis.

@en

Metformin is associated with s ...... atic review and meta-analysis.

@nl

type

label

Metformin is associated with s ...... atic review and meta-analysis.

@en

Metformin is associated with s ...... atic review and meta-analysis.

@nl

prefLabel

Metformin is associated with s ...... atic review and meta-analysis.

@en

Metformin is associated with s ...... atic review and meta-analysis.

@nl

P1433

Q37404368-C501710B-AED0-4297-96C6-152D74CA2799

P1476

Q37404368-1F6EF523-9E92-4C51-B6E9-4092B78D77C6

P2093

Q37404368-36C2C87E-DFB8-4592-A6F7-5A8EC6B03999

Q37404368-7A05F958-5DE7-46C2-817F-ED43FAF972ED

Q37404368-AA23EA8C-BFBB-40E2-ABF4-1CBCA2D1C851

Q37404368-BC71AA86-9FB3-4DE2-B85C-CF4D0716EEAB

P2860

Q37404368-029BD866-2DD4-472C-8212-F0E46116C6F8

Q37404368-042135EC-9139-4F65-AEE2-E23278F44A9F

Q37404368-0D2BEFF5-6AEC-4B07-9A2D-1EA9244227B9

Q37404368-0FBAB9BC-6B37-48A9-B270-6FEED10FC082

Q37404368-16B087F7-307A-4737-A45F-D753181B79FA

Q37404368-1766B83C-C518-45CE-B70B-BE286AB1A210

Q37404368-187FABA4-F389-4787-A790-C24E83E9295A

Q37404368-20E344E1-9254-418F-9473-77C08E84EFA6

Q37404368-2182BBE1-F562-4FAA-ACCE-EE9DEB87B944

Q37404368-31C73DBC-A433-4B01-BB43-0CCDE4ED3D00

P304

Q37404368-727B214F-3157-4D75-8C9A-F8340B0927B3

P31

Q37404368-0f640701-8356-4cb6-ab6c-270450600388

Q37404368-4D23AACF-10D5-498B-BE75-B3D617DCC718

P356

Q37404368-419B675D-A46F-4044-B078-2C086260BE1A

P433

Q37404368-5048D4DF-ABF4-410B-BE54-AFF327FDC544

P478

Q37404368-BFB72F6D-36EA-4BB8-B55C-8D1F99E59494

P577

Q37404368-B26909A1-7070-409E-ACDE-E51217A4CF02

P698

Q37404368-FB1B1BD7-21D6-45B7-B6DE-2FC02D70F08F

P921

Q37404368-3079AD43-8984-49D7-B9B3-959B44819DBD

Q37404368-4812A5C8-E17B-41D4-ACC2-A49B1D2005BA

Q37404368-6C0C498F-2AC6-46E1-8F41-357A190B1D16

Q37404368-76A3A62B-0952-4054-AA6E-241CBFE1CAB3

P932

Q37404368-FD393D2D-3183-4D83-A04E-9135F15D58A9

P356

THEONCOLOGIST.2013-0111

P1433

P1476

Metformin is associated with s ...... atic review and meta-analysis.

@en

P2093

Edward J Gorak

http://www.w3.org/2001/XMLSchema#string

Fahd Quddus

http://www.w3.org/2001/XMLSchema#string

Jie Zhou

http://www.w3.org/2001/XMLSchema#string

Ming Yin

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP

Diabetes and cancer: a consensus report.

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

Practical methods for incorporating summary time-to-event data into meta-analysis

Safety issues and prospects for future generations of PPAR modulators

Meta-analysis of genome-wide association studies with overlapping subjects

Effect of metformin on prostate cancer outcomes after radical prostatectomy

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

P304

1248-1255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0111

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24258613

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3868417

http://www.w3.org/2001/XMLSchema#string